Home > Boards > US Listed > Biotechs > Akari Therapeutics (AKTX)

Akari Announces First Quarter 2018 Financial Results and

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Rogerthat1 Member Profile
 
Followed By 44
Posts 5,565
Boards Moderated 0
Alias Born 04/03/14
160x600 placeholder
Akari Therapeutics Reports Third Quarter 2019 Financial Results And Highlights Recent Clinical Progress GlobeNewswire Inc. - 11/4/2019 8:33:48 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 10/28/2019 6:01:19 AM
Securities Registration (foreign Private Issuer) (f-1) Edgar (US Regulatory) - 10/15/2019 5:24:28 PM
Securities Registration (ads, Immediate) (f-6ef) Edgar (US Regulatory) - 10/15/2019 5:09:46 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/15/2019 7:08:47 AM
Akari Therapeutics Announces New Data from Atopic Keratoconjunctivitis (AKC) Patients Supporting the Potentially Beneficial R... GlobeNewswire Inc. - 10/14/2019 8:37:28 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/10/2019 9:03:34 AM
Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th... GlobeNewswire Inc. - 10/10/2019 8:45:02 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 10/4/2019 4:48:17 PM
Akari Therapeutics to Participate in Ladenburg Thalmann Healthcare Conference GlobeNewswire Inc. - 9/18/2019 8:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/13/2019 8:17:32 AM
Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid GlobeNewswire Inc. - 9/13/2019 8:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/10/2019 8:22:04 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/9/2019 6:01:20 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 9/6/2019 5:08:04 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/6/2019 6:01:28 AM
Akari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early September GlobeNewswire Inc. - 9/3/2019 7:00:00 AM
Securities Registration (foreign Private Issuer) (f-1/a) Edgar (US Regulatory) - 8/30/2019 4:04:38 PM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 8/30/2019 4:02:20 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/30/2019 8:13:13 AM
Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Hematopoietic Stem Cell Transplantation-Associated T... GlobeNewswire Inc. - 8/30/2019 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/29/2019 8:29:12 AM
Akari Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Clinical Progress GlobeNewswire Inc. - 8/29/2019 8:06:18 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 8/19/2019 4:05:56 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/14/2019 8:01:05 AM
Rogerthat1   Friday, 08/17/18 07:35:30 AM
Re: None
Post # of 474 
Akari Announces First Quarter 2018 Financial Results and Update on its Growing Pipeline of Phase II and Phase III Clinical Trials
August 17, 2018
Opened three clinical trials in 2018
Trials in which complement dysregulation is the primary disease driver
CAPSTONE, the Phase III trial in naïve paroxysmal nocturnal hemoglobinuria (PNH), in which patient treatment has commenced
Phase II U.S. trial for PNH patients resistant to treatment with Soliris where a patient is now being treated
Phase II trial in atypical haemolytic syndrome (aHUS) which opened Q4 2017
Trials focused on a separate group of diseases mediated by both the complement and leukotriene pathways
Phase II trial in bullous pemphigoid (BP), recently opened with data expected Q1 2019
Phase I/II trial in atopic keratoconjunctivitis (AKC) expected to commence Q3 2018, with data anticipated Q1 2019
NEW YORK and LONDON, Aug. 17, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announced its financial results for the first quarter ended March 31, 2018 and highlights its pipeline of Phase II and Phase III clinical trials.

“We are excited by the range of clinical opportunities that we are currently exploring. We look forward to providing initial clinical data from these trials starting in the fourth quarter of 2018,” commented Clive Richardson, acting Chief Executive Officer of Akari Therapeutics. “Akari does not intend to develop all of these programs through to commercialization on its own but rather, intends to partner one or more of its programs. To that end, a robust business development program has been in progress since early 2018 led by Mike Grissinger, an Akari non-executive director and pharmaceutical industry veteran who spent 22 years at Johnson & Johnson in business development leadership roles.”

Clinical Development Programs Highlights

Akari’s clinical program is divided into two separate workstreams targeting two different sets of clinical conditions. One group of diseases is where the combined inhibition of the complement and leukotriene pathways provides a potential new treatment solution for a wide range of currently poorly treated orphan inflammatory conditions. The second group of diseases are those where complement dysregulation is the primary driver.

Dual C5 and Leukotriene B4 Program

The increasing recognition that LTB4 may combine with complement dysregulation in the etiology of many autoimmune and autoinflammatory conditions has focused Akari’s clinical development on a number of poorly treated conditions where Coversin’s dual C5 and LTB4 binding provides a potential novel therapeutic solution. These programs include bullous pemphigoid (BP), an inflammatory skin disease in which current treatment is limited to steroids, and immunosuppressants and atopic keratoconjunctivitis (AKC), an eye surface inflammatory disease which can lead to permanent vision loss and for which there are few effective treatment options. Both are rare conditions for which Akari is seeking orphan designation.

Complement Program

Patient treatment in CAPSTONE, the Phase III trial in naïve PNH patients, has commenced. We anticipate introducing a new pen injector in 2019 to facilitate patient use which will accommodate a week’s supply of medication. Within the program to treat patients with a polymorphism that makes them resistant to treatment with Soliris, Akari recently began treating a second PNH patient under an investigational new drug application (IND) in the U.S. This patient has responded well (LDH <1.5xULN at day 28). In all, three Soliris resistant patients have now been treated with Coversin; two with PNH and a third with a thrombotic microangiopathy (TMA). All PNH patients remaining on treatment have the option of entering into the Akari long term safety program. Nine PNH patients have been treated in aggregate for over 11 patient years with no drug related SAEs to date.

Akari has also opened a clinical program targeting thrombotic microangiopathies (TMA) including atypical haemolytic syndrome (aHUS). We expect to provide an update on Akari’s TMA program in Q4 2018.

First Quarter 2018 Financial Results

As of March 31, 2018, the Company had cash of $23.8 million, as compared to cash of $28.1 million as of December 31, 2017.
Operating expenses, which include research and development (R&D) expenses and general and administrative (G&A) expenses, were $4.3 million in the first quarter of 2018, as compared to $8.3 million in the same quarter the prior year.
R&D expenses in the first quarter of 2018 were $1.0 million, as compared to $6.0 million in the same quarter the prior year. The decrease was due primarily to an R&D tax credit of approximately $3.8 million received in the first quarter of 2018 and lower manufacturing costs of $1.4 million associated with Coversin clinical trial material, offset by an increase in clinical trial expenses.
G&A expenses in the first quarter of 2018 were $3.3 million, as compared to $2.3 million in the same quarter last year. This increase was due primarily to higher legal, accounting and other professional service fees.
Total other income for the first quarter of 2018 was $3.0 million, as compared to total other expense of $4.3 million in the first quarter of 2017. This change was primarily attributed to $2.9 million of other income in the first quarter of 2018 compared to $4.3 million of other expense in the same period in 2017 related in both instances to the change in fair value of the stock option and warrant liabilities.
Net loss for the first quarter of 2018 was $1.3 million, compared to a net loss of $12.6 million for the same period in 2017. This year over year decrease in net loss was due primarily to lower R&D expenses in the first quarter of 2018 when compared to the same period in 2017.
About Akari Therapeutics



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist